Incyte Clinical Trial Pipeline: 62 Active Trials, 17 Changes This Month

12 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 10 with minor changes only.

Notable

TRuE-VIP1 · Ruxolitinib Cream · Nonsegmental Vitiligo

Primary completion pushed from Aug 10, 2026 to Jun 5, 2028

Also in this update: Completion pushed from Mar 13, 2027 to Dec 20, 2028

Incyte CorporationPhase 3 NCT06548360 Registry history of NCT06548360 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Notable

Axatilimab Monotherapy · Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

Primary endpoint(s) modified

Also in this update: Results posted: Oct 5, 2026

Incyte Biosciences Japan GKPhase 3 NCT06263478 Registry history of NCT06263478 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026

Show 10 trials with minor changes only

Minor

Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

Trial completed

Incyte CorporationPhase 1 NCT07588139 Registry history of NCT07588139 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib · Anemia Due to Myeloproliferative Disorders

Trial completed

Also in this update: Study completion date changed from estimate of Nov 26, 2027 to Sep 8, 2026

Incyte CorporationPhase 1/2 NCT04455841 Registry history of NCT04455841 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment · PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial completed

Incyte Biosciences International SàrlPhase 2 NCT05287113 Registry history of NCT05287113 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

MAESTRA 2 · INCB123667 Versus Investigator's Choice of Chemotherapy · Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Trial sites expanded: 192 → 197 locations

And 1 more change in the last 30 days

Incyte CorporationPhase 3 NCT07214779 Registry history of NCT07214779 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

AXemplify-357 · Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Trial sites expanded: 128 → 131 locations

Incyte CorporationPhase 3 NCT06585774 Registry history of NCT06585774 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Trial sites expanded: 280 → 293 locations

And 1 more change in the last 30 days

Incyte CorporationPhase 3 NCT07284849 Registry history of NCT07284849 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

EXCALIBUR-ET2 · INCA033989 Versus Best Available Therapy · Essential Thrombocythemia

Trial sites expanded: 175 → 178 locations

Incyte CorporationPhase 3 NCT07623200 Registry history of NCT07623200 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Minor

THRIVE · Patients at Risk for Chronic Graft-Versus-Host Disease

Trial sites expanded: 32 → 37 locations

Incyte CorporationNot specified NCT05919511 Registry history of NCT05919511 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

DAWN-303 · Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Trial sites expanded: 219 → 229 locations

Incyte CorporationPhase 3 NCT07522073 Registry history of NCT07522073 on ClinicalTrials.gov (opens the registry)

Updated Sep 15, 2026
Minor

STOP-LTR · Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Trial sites reduced: 318 → 297 locations

Incyte CorporationPhase 3 NCT06855498 Registry history of NCT06855498 on ClinicalTrials.gov (opens the registry)

Updated Sep 15, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First posted	Trial	Phase	Status
2026-10-07	NCT07862998 A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With…	Phase 2	Not Yet Recruiting
2026-10-02	NCT07854249 A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With…	Phase 1	Not Yet Recruiting
2026-10-01	NCT07853040 A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With…	Phase 1	Not Yet Recruiting
2026-09-16	NCT07823322 A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage…	Phase 2	Not Yet Recruiting

Active trials by phase

Phase 1

Phase 1/2

Phase 2

Phase 3

Not charted: 3 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 62

NCT ID	Title	Condition	Status	Updated
Phase 3
NCT06585774	A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic…	Chronic Graft-versus-host-disease	Recruiting	2026-10-09
NCT06804811	A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12…	NonSegmental Vitiligo	Recruiting	2026-10-09
NCT06855498	Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib	Hidradenitis Suppurativa (HS)	Recruiting	2026-10-09
NCT07214779	Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants…	Ovarian Cancer	Recruiting	2026-10-09
NCT07284849	A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and…	CRC (Colorectal Cancer)	Recruiting	2026-10-09
NCT07522073	A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS…	Solid Tumors	Recruiting	2026-10-08
NCT07623200	A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With…	Essential Thrombocythemia	Recruiting	2026-10-08
NCT06548360	A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric…	NonSegmental Vitiligo	Recruiting	2026-09-14
NCT06615050	A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant…	Graft-versus-host Disease (GVHD)	Recruiting	2026-05-20
NCT06263478	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy…	Chronic Graft-versus-host-disease	Active, Not Recruiting	2026-10-05
NCT07797283	Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line…	Ovarian Cancer	Not Yet Recruiting	2026-10-02
NCT04680052	A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and…	Follicular Lymphoma	Active, Not Recruiting	2026-09-04
NCT06113445	A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental…	NonSegmental Vitiligo	Active, Not Recruiting	2026-08-25
NCT06212999	A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants…	Hidradenitis Suppurativa (HS)	Active, Not Recruiting	2026-08-25
NCT06821542	A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic…	Chronic Graft-versus-host-disease	Active, Not Recruiting	2026-08-25
NCT06832618	A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and…	Atopic Dermatitis	Active, Not Recruiting	2026-08-19
NCT06959225	Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With…	Hidradenitis Suppurativa	Active, Not Recruiting	2026-07-28
NCT06958211	Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With…	Hidradenitis Suppurativa	Active, Not Recruiting	2026-07-08
NCT06516952	A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With…	Prurigo Nodularis	Active, Not Recruiting	2026-05-28
NCT05429268	Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in…	Large B-Cell Lymphoma	Active, Not Recruiting	2026-05-05
NCT06516965	A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With…	Prurigo Nodularis	Active, Not Recruiting	2026-04-14
NCT04824092	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate…	Diffuse Large B-cell Lymphoma	Active, Not Recruiting	2026-04-01
NCT06113471	A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental…	NonSegmental Vitiligo	Active, Not Recruiting	2026-03-31
Phase 2
NCT07124078	A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants…	Chronic Graft-versus-host-disease	Recruiting	2026-10-09
NCT07213973	Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With…	Hidradenitis Suppurativa (HS)	Recruiting	2026-10-09

Incyte clinical trial pipeline

What changed in the last 30 days

TRuE-VIP1 · Ruxolitinib Cream · Nonsegmental Vitiligo

Axatilimab Monotherapy · Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib · Anemia Due to Myeloproliferative Disorders

Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment · PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

MAESTRA 2 · INCB123667 Versus Investigator's Choice of Chemotherapy · Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

AXemplify-357 · Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

EXCALIBUR-ET2 · INCA033989 Versus Best Available Therapy · Essential Thrombocythemia

THRIVE · Patients at Risk for Chronic Graft-Versus-Host Disease

DAWN-303 · Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

STOP-LTR · Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

New trial filings, last 30 days

Active trials by phase

Active trials top 25 of 62

Disease areas by active trials, top 10 of 20